Compare AbCellera Biologics Inc (ABCL) vs Herbalife Nutrition Ltd (HLF) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Herbalife (HLF) trades at $13.14, showing modest daily gains of 0.23%. The stock presents a mixed technical picture with neutral signals from oscillators and bearish moving averages. Fundamentally, HLF maintains strong gross margins of 77.78% and attractive valuation metrics including a P/E of 5.64 and P/S of 0.26. Recent Q1 2026 earnings beat expectations with $0.64 EPS versus $0.607 expected, while the company completed a significant $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.

HLF offers value investment appeal with deep discount valuations and improving debt trends, though negative shareholder equity and competitive pressures in the nutrition space present ongoing challenges. Analyst sentiment leans bullish with 57.7% buy ratings, but the stock faces headwinds from its multi-level marketing model scrutiny and regional market volatility. The upcoming Q2 2026 earnings on August 5 will be crucial for validating recent guidance increases.